Merus N.V.

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:03 2024-04-23 pm EDT			5-day change	1st Jan Change
40.75 ^USD	+0.74%		+1.09%	+48.18%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Mar. 28	Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target	MT

Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

November 10, 2021 at 08:02 am EST

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).

The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am GMT/3:00 am ET on the Investors page of the Company's website and remain available for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

Investor and Media Inquiries:

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl

Source: Merus N.V.

2021 GlobeNewswire, Inc., source Press Releases

Latest news about Merus N.V.

Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	Apr. 19	MT
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target	Mar. 28	MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating	Mar. 07	MT
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies	Mar. 06	MT
Gilead, Merus to Collaborate on Trispecific Antibody Research	Mar. 06	DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers	Mar. 06	CI
Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.	Mar. 04	CI
Needham Raises Price Target on Merus to $65 From $42, Keeps Buy Rating	Mar. 04	MT
Merus Full-Year 2023 Net Loss Widens, Revenue Increases	Feb. 28	MT
Earnings Flash (MRUS) MERUS N.V. Posts 2023 Revenue $43.95M	Feb. 28	MT
Merus N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Merus Power Lands EUR15 Million Order for Battery Energy Storage System	Feb. 14	MT
Earnings Flash (MRUS) MERUS N.V. Reports Q3 Revenue $11M	Nov. 02	MT
Merus N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Stifel Adjusts Merus' Price Target to $40 From $45, Maintains Buy Rating	23-10-24	MT
Merus Says Interim Data Show Zenocutuzumab Demonstrates 'Robust and Durable' Responses in Cancer Patients	23-10-23	MT
Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer	23-10-23	CI
Certain Options of Merus N.V. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Restricted Share Units of Merus N.V. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Common Shares of Merus N.V. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
TD Cowen Starts Merus With Outperform Rating	23-08-21	MT
Citigroup Adjusts Merus' Price Target to $46 From $48, Keeps Buy Rating	23-08-10	MT
Merus Prices $150 Million Common Stock Offering	23-08-10	MT
Merus Prices $150 Million Public Offering of Shares	23-08-10	MT
Stifel Adjusts Price Target on Merus to $45 From $44, Maintains Buy Rating	23-08-08	MT

Chart Merus N.V.

Duration

Period

More charts

Company Profile

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Merus N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.82 USD

Average target price

60.45 USD

Spread / Average Target

+48.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MERUS N.V.	+48.18%	2.4B
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+3.26%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.87%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs